Adoptive cell therapy, the transfer of living immune cells to a patient to fight cancer, has been revolutionized by CAR-T cells. However, the success of CAR-T therapy has been largely confined to certain hematologic (blood) cancers. For solid tumors—which account for the vast majority of cancer cases—the path has been far more difficult. This has intensified research into alternative cell types, with natural killer (NK) cells emerging as a prominent candidate.

Crucially, NK cell therapy for solid tumors remains investigational. It is not an established standard of care, and its efficacy has not been proven in large, randomized clinical trials. This article provides a conservative, evidence-based overview of the science, the significant barriers that must be overcome, the current state of clinical research, and the safety considerations for this developing field.

The Innate Power of Natural Killer Cells

NK cells are a type of cytotoxic lymphocyte and a key component of the innate immune system. Unlike T cells, they do not require prior sensitization or specific antigen presentation to recognize and kill target cells. They employ a sophisticated surveillance system based on a balance of signals from activating and inhibitory receptors on their surface [1].

Once activated, NK cells kill target cells directly and also release cytokines like interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which can recruit and activate other immune cells, shaping a broader anti-tumor response.

Sources and Types of Therapeutic NK Cells

A major focus of clinical development is generating large numbers of functional NK cells for infusion. Unlike patient-specific (autologous) CAR-T cells, many NK cell products are being developed as allogeneic, "off-the-shelf" therapies derived from healthy donors, which offers significant logistical and cost advantages [6].

Before infusion, patients typically undergo lymphodepleting chemotherapy (e.g., with cyclophosphamide and fludarabine). This conditioning regimen reduces the number of the patient's own immune cells, creating "space" for the infused NK cells to expand and reducing competition for essential growth factors like IL-15.

The Gauntlet: Why Solid Tumors Resist NK Cell Attack

While the biology is promising, the clinical reality is that solid tumors have evolved a formidable fortress of defenses. An infused NK cell must navigate a multi-step journey, and failure at any stage can lead to therapeutic failure [8].

Diagram illustrating the barriers NK cells face in the solid tumor microenvironment (TME), including trafficking failure and immunosuppressive factors.
The solid tumor microenvironment (TME) presents multiple barriers to NK cell therapy, including poor trafficking, metabolic challenges, and suppressive signals.

Trafficking and Infiltration Failure

The first major hurdle is simply getting to the tumor. Systemically infused NK cells must exit the bloodstream and migrate through dense tissue to reach cancer cells. This process, known as trafficking, is often inefficient. Solid tumors frequently do not express the correct chemokines (homing signals) to match the chemokine receptors on standard expanded NK cells. This "chemokine-receptor mismatch" means the NK cells are not effectively recruited to the tumor site [4]. Even if they are recruited, abnormal tumor vasculature and a dense, fibrotic extracellular matrix (stroma) can form a physical barrier, preventing deep infiltration.

The Suppressive Tumor Microenvironment (TME)

Should NK cells successfully infiltrate the tumor, they enter a hostile microenvironment actively designed to shut them down. The TME is a complex ecosystem of cancer cells, blood vessels, immune cells, and signaling molecules that promotes tumor growth and suppresses anti-tumor immunity.

Metabolic Warfare and Hypoxia

Tumors are metabolically demanding, rapidly consuming glucose and other nutrients. This creates a nutrient-poor environment where NK cells struggle to compete. The high rate of glycolysis by tumor cells leads to the accumulation of lactate, which acidifies the TME and directly impairs NK cell metabolism and function. Additionally, adenosine, which accumulates in the hypoxic (low-oxygen) core of many tumors, can bind to A2A receptors on NK cells and deliver a powerful inhibitory signal [3]. Hypoxia itself also directly suppresses NK cell activity.

Limited In-Vivo Persistence and Expansion

For adoptive cell therapy to be effective, the infused cells must survive, expand, and persist long enough to eliminate the tumor. Many early NK cell products have demonstrated very poor persistence, often becoming undetectable within days or weeks of infusion. This is partly due to a lack of appropriate cytokine support; while high-dose IL-2 was used in early studies, it is highly toxic and preferentially expands suppressive Tregs. IL-15 is now recognized as a more critical cytokine for NK cell survival and function, but maintaining adequate levels in vivo remains a challenge [15].

Antigen Heterogeneity and Escape

Even for highly targeted approaches like CAR-NK cells, solid tumors pose a unique problem. Unlike blood cancers where the target antigen is often uniformly expressed, solid tumors are highly heterogeneous. Some cancer cells within the same tumor may not express the target antigen, allowing them to escape destruction and eventually regrow. This phenomenon, known as antigen escape, is a major cause of relapse after targeted therapies.

Engineering a Better Killer: Strategies Under Investigation

The field is now focused on developing "next-generation" NK cell products engineered to overcome these specific barriers. Most of these strategies are still in preclinical or early-phase clinical testing.

Interpreting the Clinical Evidence in Solid Tumors

Despite immense preclinical enthusiasm, the clinical data for NK cell therapy in solid tumors remains preliminary and must be interpreted with extreme caution. The field is dominated by small, non-randomized, early-phase (Phase I) studies focused primarily on safety and feasibility.

A Cautious Look at a Recent Meta-Analysis

A 2024 systematic review and meta-analysis by Park et al. examined 31 prospective studies involving approximately 600 patients with various solid tumors [5]. In a subgroup of studies published from 2011–2020, the pooled objective response rate was 38.4% and the disease-control rate was 72.7%. These estimates must not be mistaken for proof that NK cells alone produced the outcomes: study designs, cancers, cell products, local therapies, and combination regimens varied substantially. The heterogeneity and absence of randomized comparators in most studies are the critical takeaway:

Therefore, the pooled response rates from this meta-analysis do not represent the efficacy of NK cell monotherapy. They are a signal that in some patients, under some conditions (often with concurrent therapy), anti-tumor activity can be observed. It underscores that we are still in the early stages of identifying which products, for which patients, and in which combinations, might be effective.

Notable Early-Phase Trials

Individual trial reports provide more specific, albeit small-scale, insights. For example, early Phase I studies of irradiated NK-92 cells, alone or with IL-2, showed the treatment was generally well-tolerated in patients with advanced renal cell carcinoma and melanoma, but clinical responses were minimal and transient [9]. A Phase I/II study using haploidentical donor NK cells combined with chemotherapy in patients with refractory ovarian and breast cancer found that the cells could be detected transiently but did not expand significantly, leading to limited clinical benefit [10]. More recently, a report on just three patients with colorectal cancer liver metastases described the local, intra-arterial delivery of NKG2D-CAR-NK cells, reporting some reduction in tumor markers and radiologic changes, but this is far too small to draw conclusions [11]. Numerous early-phase trials of CAR-NKs, such as those targeting HER2 in glioblastoma, are ongoing, but published data remains sparse. Trial registration is a sign of activity, not proof of efficacy.

Table 1: Interpreting NK Cell Therapy Evidence for Solid Tumors
Observation from Early Trials Cautious Interpretation & Limitations
Reports of "disease control" or stable disease in some patients. This often includes patients whose tumors did not shrink but simply did not grow for a period. It is not equivalent to a tumor response and can be part of the natural history of some cancers.
A small percentage of patients show partial tumor shrinkage (partial response). These responses are encouraging but often occur in patients also receiving chemotherapy or antibodies. It is difficult to attribute the effect solely to the NK cells. Durability of these responses is a key unknown.
Infused NK cells are generally safe with a lower rate of severe CRS and neurotoxicity compared to CAR-T cells. This is a significant advantage, but "lower risk" does not mean "no risk." The safety profile can change with genetic engineering, higher doses, and different cytokine support regimens.
One meta-analysis reported a 38.4% objective response rate in a 2011–2020 subgroup. This pooled estimate spans highly diverse, small, mostly non-randomized studies with frequent co-therapies. It is not a reliable predictor of benefit for an individual patient or a specific product, and it does not prove survival benefit.

Safety and Risks of NK Cell Therapy

A key motivation for developing NK cell therapies is their generally favorable safety profile compared to T-cell therapies. Severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which can be life-threatening with CAR-T cells, have been observed much less frequently and with lower severity in most NK cell trials to date. However, this does not mean the therapy is without risk.

The requirement to irradiate the NK-92 cell line to prevent malignant transformation inherently limits its persistence and, consequently, its potential for durable efficacy.

Frequently Asked Questions

Is NK cell therapy approved for solid tumors?

No NK-cell product appears on the U.S. FDA’s approved cellular and gene therapy list for solid tumors as of this article’s review date. Regulatory status differs by jurisdiction and exact product; patients should verify it with the relevant regulator and oncology team. The products discussed here remain investigational and should be accessed through appropriately registered clinical studies or regulated pathways.

How is NK cell therapy different from CAR-T cell therapy?

Both are forms of adoptive cell therapy. The main differences are the cell type (NK vs. T cell), the source (many NK products are "off-the-shelf" allogeneic, while most CAR-T are autologous), and the safety profile (NK cells have shown a lower risk of severe CRS and neurotoxicity to date).

Can any patient with a solid tumor join an NK cell trial?

No. Clinical trials have very strict inclusion and exclusion criteria based on cancer type, stage, prior treatments, organ function, and overall health. Most current trials are for patients with advanced or refractory cancers who have exhausted standard treatment options.

What is the difference between "unmodified" and "CAR-NK" cells?

Unmodified (or conventional) NK cells rely on their natural receptors to find and kill cancer cells. CAR-NK cells are genetically engineered with a Chimeric Antigen Receptor (CAR) that directs them to a specific antigen on the tumor surface, enhancing their specificity and killing power.

Does the evidence show NK cell therapy can cure solid cancers?

No. There is currently no evidence from large, controlled trials to suggest that NK cell therapy can cure solid cancers. The goal in current early-phase trials is to establish safety and look for early signals of anti-tumor activity, not to demonstrate cures.

Limitations and Medical Disclaimer

NK cell therapy for solid tumors is an experimental treatment that has not been proven to be safe or effective. The information in this article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The field is evolving rapidly, and data from small, early-phase studies should not be interpreted as a guarantee of clinical benefit. No claims of cure or specific outcomes are made. Patients should discuss all standard-of-care treatment options and the possibility of enrolling in a formal clinical trial with their oncology team. Decisions about medical care should be made in consultation with a qualified healthcare provider who can assess an individual's specific situation.

References

  1. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-49. doi:10.1126/science.1198687 ↩
  2. Morvan MG, Lanier LL. NK cells and cancer: you can teach an old dog new tricks. Nat Rev Cancer. 2016;16(1):7-19. doi:10.1038/nrc.2015.5 ↩
  3. Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nat Immunol. 2020;21(8):835-847. doi:10.1038/s41590-020-0728-z ↩
  4. Melaiu O, Lucarini V, Cifaldi L, et al. The Bull in a China Shop: The NK-Cell Stand-Off in the Tumor Microenvironment. Front Immunol. 2020;10:3038. doi:10.3389/fimmu.2019.03038 ↩
  5. Park H, Kim G, Kim N, Ha S, Yim H. Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front Immunol. 2024;15:1454427. doi:10.3389/fimmu.2024.1454427 ↩
  6. Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200-217. doi:10.1038/s41573-019-0052-1 ↩
  7. Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85-100. doi:10.1038/s41571-020-0426-7 ↩
  8. Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Current Opinion in Immunology. 2018;51:146-153. doi:10.1016/j.coi.2018.03.013 ↩
  9. Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10(6):625-632. doi:10.1080/14653240802301872 ↩
  10. Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy in patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98-107. doi:10.3109/14653249.2010.515582 ↩
  11. Xiao L, Cen D, Gan H, et al. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. Mol Ther. 2019;27(6):1114-1125. doi:10.1016/j.ymthe.2019.03.011 ↩
  12. Hu Z, Xu X, Wei H. The Adverse Impact of Tumor Microenvironment on NK-Cell. Front Immunol. 2021;12:633361. doi:10.3389/fimmu.2021.633361 ↩
  13. Marofi F, Rahman HS, Thangavelu L, et al. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Res Ther. 2021;12:200. doi:10.1186/s13287-021-02251-7 ↩
  14. Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181-192.e5. doi:10.1016/j.stem.2018.06.002 ↩
  15. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin-15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180(4):1395-1403. doi:10.1084/jem.180.4.1395 ↩